Effect of topical beclomethasone on histamine-induced increases in nasal airflow resistance and secretion in perennial rhinitis

1993 ◽  
Vol 18 (4) ◽  
pp. 285-290 ◽  
Author(s):  
J.M. STUDHAM ◽  
F. O'CONNELL ◽  
J. HENDERSON ◽  
V.E. THOMAS ◽  
R.W. FULLER ◽  
...  
2009 ◽  
Vol 30 (11) ◽  
pp. 1197-1209 ◽  
Author(s):  
T Seppänen ◽  
M Koskinen ◽  
T M Seppänen ◽  
O-P Alho

CHEST Journal ◽  
2001 ◽  
Vol 120 (2) ◽  
pp. 397-401 ◽  
Author(s):  
Anne Marie Lorino ◽  
Marie Pia d'Ortho ◽  
Estelle Dahan ◽  
Olivier Bignani ◽  
Carine Vastel ◽  
...  

CHEST Journal ◽  
2000 ◽  
Vol 118 (2) ◽  
pp. 366-371 ◽  
Author(s):  
Anne-Marie Lorino ◽  
Hubert Lorino ◽  
Estelle Dahan ◽  
Marie Pia d’Ortho ◽  
André Coste ◽  
...  

CHEST Journal ◽  
1978 ◽  
Vol 74 (4) ◽  
pp. 408-410 ◽  
Author(s):  
Kiumars Saketkhoo ◽  
Adolph Januszkiewicz ◽  
Marvin A. Sackner

1987 ◽  
Vol 1 (3) ◽  
pp. 141-146
Author(s):  
Eli O. Meltzer ◽  
H. Alice Orgel ◽  
Bernard A. Berman ◽  
David S. Pearlman ◽  
Raymond G. Slavin ◽  
...  

Fluocortin butyl (FCB) is a new topically active steroid. In this 12-week, parallel, multicenter study, 157 symptomatic patients, aged 12–69 years, with moderate to severe perennial rhinitis were randomized to receive either FCB powder or beclomethasone dipropionate (BDP) aerosol spray intranasally. Four symptoms and four signs were scored at the start of the study and every 2 weeks for 12 weeks. Use of concomitant medications and dosage of intranasal medication were monitored. The nasal cytology and nasal cultures of randomly selected patients were examined. At one center 40 patients had rhinomanometric evaluation. Significant decrease from baseline in symptoms and signs was evident by 2 weeks and then continued at a slower rate for up to 12 weeks with both FCB and BDP. There was also an increase in nasal airflow as shown by rhinomanometry and a decrease in concomitant medications. There was no significant difference in efficacy between the two medications. Both drugs were tolerated with minimal side effects. With a lower incidence of nasal irritation and a simple delivery system, FCB has a definite place in the treatment of rhinitis.


1997 ◽  
Vol 11 (6) ◽  
pp. 415-420 ◽  
Author(s):  
Philip Cole

Examination of rhinomanometric records of 2500 referred adult patients revealed 891 unobstructed noses (Rn <0.25 Pa/cm3/sec). Topical decongestant reduced respiratory airflow resistances of these noses by ⅓ on average indicating the extent of the vascular component. Alar retraction, which minimizes resistance of the compliant portion of the nose, reduced unilateral nasal resistances by as much as ⅔, establishing the alar lumen as a major resistive segment of the unobstructed nasal airway. The nasal resistances that persisted after decongestion and alar retraction predominated in the immediately adjacent cavum. There remained 1350 noses designated as obstructed by clinician assessment of the records and suitable for analysis. Application of topical decongestant, which minimized the mucovascular component of resistance, revealed ⅘ of residual obstructions to be principally unilateral and were designated as structural. Half these structural obstructions were restricted to the alar lumen and half included the alar lumen and the adjoining cavum. Obstructions confined to the cavum were less than 2%. A further ⅕ of the nasal obstructions were bilateral and their resistances, which were markedly elevated in many cases, were substantially reduced by topical decongestant indicating an extensive vascular component. They were designated as mucosal.


Sign in / Sign up

Export Citation Format

Share Document